Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2024-06-17 Capital/Financing Update
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
Capital/Financing Update Classification · 100% confidence The document is an announcement by BioPorto A/S regarding a private placement of 50,000,000 new shares to raise capital. It details the offering size, subscription price, use of proceeds, and the timeline for the capital increase. This falls under the category of capital raising and financing activities, which is specifically defined as 'CAP'.
2024-06-17 English
Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'BioPorto Annual Report 2022' and contains detailed sections typical of an annual report, including a letter to stakeholders, strategy, consolidated financial highlights, risk management, governance, corporate social responsibility, shareholder matters, board of directors, executive management, financial review, financial statements, notes to financial statements, statement by the board and management, and an independent auditor's report. The content includes comprehensive financial and strategic information for the year 2023, including revenue figures, future plans, FDA clearance details, and management commentary. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-04 English
Earnings Release 2023
Earnings Release Classification · 100% confidence The document is titled 'Correction: BioPorto Announces Annual Results for 2023' and explicitly states 'Correction: Updated Annual Report attached'. It provides key financial highlights for the year ended December 31, 2023, and includes an outlook for 2024. This content strongly suggests it is an announcement related to the full annual financial performance. However, the document itself is a press release format (short, dated April 4, 2024) that explicitly points to attached documents, including an 'Annual Report 2023'. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement pointing to the full report should be classified as a Report Publication Announcement (RPA). While the content summarizes the annual results (which might suggest 10-K or ER), the structure and explicit mention of attachments, combined with the short length relative to a full 10-K, point towards RPA. FY 2023
2024-04-04 English
Correction: BioPorto Announces Annual Results for 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2023' for BioPorto A/S. It contains a comprehensive overview of the company's strategy, financial highlights, governance, and detailed financial statements, which aligns with the definition of a 10-K (Annual Report). FY 2023
2024-04-04 English
Correction: BioPorto Announces Annual Results for 2023
Remuneration Information Classification · 100% confidence The document is a 'Remuneration Report 2023' for BioPorto A/S. It details the compensation, incentive programs, and shareholdings of the Board of Directors and Executive Management. According to the provided filing definitions, reports detailing compensation for top executives and directors are classified under 'DEF 14A' (Remuneration Information).
2024-04-04 English
Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'BioPorto Annual Report 2023' and contains detailed sections typical of an annual report, including a letter to stakeholders, strategy, financial highlights, governance, corporate social responsibility, shareholder matters, board and management information, financial management, financial review, financial statements, notes, and an independent auditor's report. The content includes comprehensive discussion of company strategy, financial results, regulatory milestones (FDA clearance), and future outlook. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.